Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval

September 19, 2016 9:59 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment